Cellyan Biotechnology Co., LtdHKPD

NasdaqHealthcareWholesale-Drugs, Proprietaries & Druggists' Sundries
Price (close)
$0.12
Market cap
$6.0M
P/E
—
Revenue (FY)
$20.3M
Net income
-$27,056
Dividend yield
—
1-year total return
-93.1%
Net margin
-0.1%
Revenue growth
21.7%
Debt / equity
0.30x

What Cellyan Biotechnology Co., Ltd does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year2022202320242025
Revenue—$12.6M$16.7M$20.3M
Net income—$998,196$1.3M-$27,056
Free cash flow—$1.6M-$447,066$499,298

More on HKPD.

Figures from Cellyan Biotechnology Co., Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.